NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) Director James N. Topper bought 4,005 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was purchased at an average cost of $21.02 per share, with a total value of $84,185.10. Following the completion of the transaction, the director now owns 3,012,434 shares in the company, valued at $63,321,362.68. This represents a 0.13 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
NewAmsterdam Pharma Price Performance
Shares of NASDAQ NAMS opened at $23.50 on Friday. The business has a 50-day moving average of $22.24 and a two-hundred day moving average of $20.43. The company has a market capitalization of $2.17 billion, a price-to-earnings ratio of -9.04 and a beta of -0.06. NewAmsterdam Pharma has a 1 year low of $15.19 and a 1 year high of $27.29.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. As a group, equities research analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.
Analysts Set New Price Targets
Several brokerages have commented on NAMS. Scotiabank raised their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 27th. Needham & Company LLC decreased their target price on NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Royal Bank of Canada restated an "outperform" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Finally, HC Wainwright reissued a "buy" rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $43.80.
Read Our Latest Stock Report on NewAmsterdam Pharma
Institutional Trading of NewAmsterdam Pharma
Several institutional investors have recently modified their holdings of NAMS. TimesSquare Capital Management LLC raised its stake in NewAmsterdam Pharma by 3.7% during the 3rd quarter. TimesSquare Capital Management LLC now owns 255,245 shares of the company's stock worth $4,237,000 after acquiring an additional 9,160 shares in the last quarter. Lisanti Capital Growth LLC purchased a new position in shares of NewAmsterdam Pharma during the third quarter worth about $700,000. GSA Capital Partners LLP increased its position in shares of NewAmsterdam Pharma by 79.9% during the third quarter. GSA Capital Partners LLP now owns 66,402 shares of the company's stock worth $1,102,000 after purchasing an additional 29,496 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of NewAmsterdam Pharma by 8.9% in the 3rd quarter. Jennison Associates LLC now owns 1,020,278 shares of the company's stock valued at $16,937,000 after purchasing an additional 83,115 shares during the last quarter. Finally, HealthInvest Partners AB boosted its position in shares of NewAmsterdam Pharma by 83.4% in the 3rd quarter. HealthInvest Partners AB now owns 138,983 shares of the company's stock valued at $2,307,000 after purchasing an additional 63,189 shares during the period. Hedge funds and other institutional investors own 89.89% of the company's stock.
NewAmsterdam Pharma Company Profile
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
